Additional data demands delay Biomarin's hemophilia drug submission in US
![Photo: Manuel Balce Ceneta/AP/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14096298.ece/ALTERNATES/schema-16_9/22089574761942-5708x3214ma.jpg)
Gene therapy valoctocogene roxaparvovec will not be up for re-evaluation by the US Food and Drug Administration (FDA) until September, biotech firm Biomarin has announced in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.